<code id='3623D8DDAD'></code><style id='3623D8DDAD'></style>
    • <acronym id='3623D8DDAD'></acronym>
      <center id='3623D8DDAD'><center id='3623D8DDAD'><tfoot id='3623D8DDAD'></tfoot></center><abbr id='3623D8DDAD'><dir id='3623D8DDAD'><tfoot id='3623D8DDAD'></tfoot><noframes id='3623D8DDAD'>

    • <optgroup id='3623D8DDAD'><strike id='3623D8DDAD'><sup id='3623D8DDAD'></sup></strike><code id='3623D8DDAD'></code></optgroup>
        1. <b id='3623D8DDAD'><label id='3623D8DDAD'><select id='3623D8DDAD'><dt id='3623D8DDAD'><span id='3623D8DDAD'></span></dt></select></label></b><u id='3623D8DDAD'></u>
          <i id='3623D8DDAD'><strike id='3623D8DDAD'><tt id='3623D8DDAD'><pre id='3623D8DDAD'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:43275
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Here’s what’s in the FDA plan to include pregnant women in clinical trials
          Here’s what’s in the FDA plan to include pregnant women in clinical trials

          AdobeTheFDAhastakenabigstepinencouragingdrugcompaniestoincludepregnantwomeninclinicaltrials,issuinga

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

          CDCWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyour